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Radiation therapy is an important component of cancer therapy for early stage as well
as locally advanced lung cancer. The use of F18 FDG PET/CT has come to the forefront
of lung cancer staging and overall treatment decision-making. FDG PET/CT parameters
such as standard uptake value and metabolic tumor volume provide important prognostic
and predictive information in lung cancer. Importantly, FDG PET/CT for radiation planning
has added biological information in deﬁning the gross tumor volume as well as involved
nodal disease. For example, accurate target delineation between tumor and atelectasis
is facilitated by utilizing PET and CT imaging. Furthermore, there has been meaningful
progress in incorporating metabolic information from FDG PET/CT imaging in radiation
treatment planning strategies such as radiation dose escalation based on standard uptake
value thresholds aswell as using respiratory-gated PET and CT planning for improved target
delineation of moving targets. In addition, PET/CT-based follow-up after radiation therapy
has provided the possibility of early detection of local as well as distant recurrences after
treatment. More research is needed to incorporate other biomarkers such as proliferative
and hypoxia biomarkers in PET as well as integrating metabolic information in adaptive,
patient-centered, tailored radiation therapy.
Keywords: image-guided radiation therapy, intensity-modulated radiation therapy, lung cancer, PET/CT, radiother-
apy planning, stereotactic body radiation therapy
INTRODUCTION
Lung cancer is the leading cause of cancer death. In 2007, the
annual incidence was approximately 20,000 and almost 16,000
people died from lung cancer (http://www.cdc.gov/Features/
dsLungCancer). The overall 5-year survival of patients diag-
nosed with lung cancer is approximately 14%. Only one-third
of presenting patients are eligible for surgery (Rubin, 2001).
Although surgery is the therapy of choice in early-stage lung
cancer, radiation therapy plays a major role in patients who are
either medically or technically inoperable and not candidates for
surgery. Recent advances in radiation therapy for non-small cell
lung cancer (NSCLC) including intensity-modulated radiother-
apy (IMRT), image-guided radiotherapy (IGRT), and stereotactic
body radiotherapy (SBRT) have enabled higher radiation doses to
be delivered to tumors which increases the tumor local control
probability while reducing doses to surrounding normal tissue.
This has led to the ability to reduce radiation-induced short-
term and long-term toxicities. Although CT-based planning is
the standard approach, CT-based planning only provides anatom-
ical information. Incorporating PET into radiation treatment
planning adds a layer of biological information, glucose consump-
tion. Improved targeting of viable tumor based on delineation of
metabolically active tumor by F18 FDG PET/CT has been the basis
of increased adoption of PET-based radiation treatment planning.
Intensity-modulated radiation therapy uses non-uniform radi-
ation beam intensities in order to improve conformal target
coverage especially for irregularly shaped tumors. This allows for
dose escalation along with better sparing of surrounding normal
tissues leading to improved treatment outcomes and decreased
radiation-induced toxicity (Teh et al., 1999). IGRT incorporates
planar and volumetric imaging information (X-ray, CT, and
Cone-Beam CT-based) to improve the accuracy of daily patient
positioning with the possibility of adaptation and modiﬁcation of
the target volume when the anatomy of the tumor and or nor-
mal organs changes during therapy (Wurm et al., 2006). Adaptive
radiotherapy, a process by which radiation plans are modiﬁed
based on changes in tumor volume during treatment also enables
dose escalation and minimization of normal tissue irradiation
(Guckenberger et al., 2011).
Stereotactic radiosurgery (SRS) and SBRT are techniques for
delivering very high doses in a single or in a few fractions
(hypofractionation) in order to shorten treatment duration and
escalate the biological equivalent dose (Dworzecki et al., 2012).
SRS and SBRT require a high degree of precision requiring
tumor motion compensation and improved targeting of metabol-
ically active tumor. Radiation Therapy Oncology Group (RTOG)
recently completed a multi-institutional North American phase II
trial (RTOG 0236) using 54 Gy in three fractions SBRT for T1-
T2N0M0 NSCLC (Timmerman et al., 2010). Of the 55 evaluable
patients, the 3-year primary tumor control rate was 97.6%. The
median overall survival in the cohort was 48.1 months. There were
only nine patients that had grade III or higher treatment-related
www.frontiersin.org July 2012 | Volume 2 | Article 71 | 1
“fonc-02-00071” — 2012/10/24 — 19:59 — page 2 — #2
Lee et al. PET/CT for radiotherapy in lung cancer
toxicity, and there were no deaths due to treatment. These results
are better than historical data using conventionally fractionated
radiotherapy for early-stage NSCLC.
The above-mentioned approaches to radiation therapy for lung
tumors beneﬁt from an accurate delineation of metabolically
active primary tumor using PET/CT, which enables suitable dose
escalation strategies to highly metabolic tumor volumes (MTVs).
STAGING WITH F18 FDG PET/CT FOR THERAPY DECISION
Accurate staging of NSCLC is essential for appropriate therapy
selection. F18 FDG PET/CT shows higher accuracy compared
to CT for mediastinal and distant metastases and affects man-
agement for approximately one-third of patients (Kernstine et al.,
2002). Increased FDG uptake in metastatic nodes not signiﬁcantly
enlarged by CT criteria is the reason for superior sensitivity of
PET/CT. PET/CT is also able to differentiate metabolically active
lung tumor from atelectasis (Nestle et al., 1999; Figures 1–6) as
well as intratumoral necrotic zones which helps better determine
RT target volumes. It is therefore possible to escalate doses to
viable tumor and minimizing radiation to normal tissue, which
may reduce long-term ﬁbrosis and related sequelae (De Ruysscher
et al., 2005).
Delineation of mediastinal nodes by PET/CT is important for
decision-making regarding surgery vs. radiation. NSCLC patients
with no involved lymph nodes (N0) or only positive hilar nodes
(N1) may have operable disease if the primary tumor is judged
to be resectable. In non-operable patients who have T1 or T2
disease without nodal metastases (N0), SBRT delivering 60–
80 Gray in 6–8 fractions can potentially achieve excellent local
control. Accurate detection of mediastinal lymph node metas-
tases is critical for determining the application of SBRT for
patients with early-stage NSCLC. Li et al. (2012) in a multi-center
FIGURE 1 | Squamous cell carcinoma in left upper lobe with
associated atelectasis. F18 FDG PET/CT shows large hypermetabolic
suprahilar mass with a small FDG avid left paratracheal lymph node
metastases. F18 FDG PET/CT deﬁnes the extent of metabolically active
tumor and differentiates viable tumor from adjacent atelectasis. FDG avid
solitary mediastinal lymph node metastases were also detected by PET/CT
while CT was equivocal. However, the major impact of PET/CT was for
guiding GTV with incorporating metabolically active tumor and nodal
metastases and excluding atelectatic lung tissue in order to deliver higher
dose to the tumor and decrease radiation to normal lung.
FIGURE 2 |The same patient in Figure 1A was treated with concurrent
chemoradiation with a total dose of 66 Gy in 2 Gy fractions.
FIGURE 3 | Post-radiation therapy F18 FDG PET/CT shows significant
decrease in tumor volume but as well as SUVmax. However,
considerable amount of metabolically active residual tumor is evident in
post-therapy PET suggesting inadequate local control. Note absence of
atelectasis with reinﬂation of the lung secondary to decrease in tumor
volume. Minor post-radiation inﬂammatory changes in the posterior lung
are characterized by mild increased FDG uptake. Data courtesy of M. D.
Anderson, Cancer Center, Orlando, FL, USA.
study performed preoperative F18 FDG PET/CT in 200 patients.
The PET ﬁndings related to lymph nodes were conﬁrmed with
histopathological examination of the surgical specimen. PET/CT
demonstrated high speciﬁcity (83%) and negative predictive value
(NPV) (91%) for presence of mediastinal lymph node metastases.
The conclusion was that a negative PET/CT for mediastinal nodal
metastases was sufﬁcient evidence to justify treating the primary
tumor with SBRT.
PET/CT can change the radiation ﬁeld signiﬁcantly by includ-
ing FDG avid non-enlarged metastatic lymph nodes within the
treatment ﬁeld. While the sensitivity of CT for mediastinal
node metastases detection is 56%, for F18 FDG PET/CT, this
is 83% for all stages, 91% when the CT scan shows enlarged
lymph nodes, and 70% for normal-sized lymph nodes (Hell-
wig et al., 2009). In view of the high NPV of F18 FDG PET/CT
for nodal metastases (>90%), routine elective nodal radiation is
no longer recommended (Senan et al., 2004). It has been shown
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FIGURE 4 | F18 FDG PET/CT of a patient with medically inoperable,
centrally located, stage I squamous cell carcinoma of the left lower
lobe causing obstructive left lower lung collapse. Contrast CT is unable
to differentiate tumor from adjacent collapsed left lower lobe. PET only
image of the same axial slice demonstrates FDG avidity of only the tumor
and differentiates metabolically active tumor from adjacent collapsed lung.
PET was used for stereotactic body radiation therapy image-guided
treatment planning to target the FDG avid tumor. Patient received 50 Gy in
four fractions in May 2010. Early post-SBRT PET/CT imaging was performed
in August 2010 to assess therapy response, which showed a complete
metabolic response and re-inﬂation of the left lower lobe. The patient is
currently free of local or distant recurrence or post-radiation complications
with improved exercise tolerance and lowered oxygen consumption.
Courtesy of UCLA Radiation Oncology SBRT program.
that irradiation of only PET positive lymph nodes is safe which
reduces the high-dose volume (van Der Wel et al., 2005). Selec-
tive mediastinal lymph node irradiation based on PET with 18F
FDG yielded a low rate of treatment failure for isolated nodes,
suggesting that reducing the target volume does not result in com-
promised local control (De Ruysscher et al., 2005). In a dosimetric
study, van Der Wel et al. (2005) reported that for 21 patients with
N2 or N3 NSCLC, the use of PET/CT in radiotherapy planning
resulted in a lower level of radiation exposure of the esophagus
and the lungs, allowing a signiﬁcant increase in the dose deliv-
ered to the tumor. This is to a large extent due to avoidance of
prophylactic radiation to mediastinal nodes if they are PET/CT
negative. Similarly, dose escalation in PET positive areas with
omitting of elective nodal irradiation in small-cell lung cancer was
studied by Shirvani et al. (2010). Sixty-two patients were treated
with IMRT based on PET/CT. The RT plan did not include elec-
tive nodal stations if they were PET negative. Only one patient
out of 62 had recurrence in unirradiated elective nodes. Plan-
ning the target volume based on PET, 45 Gy was delivered in
30 twice-daily fractions. Most recurrences were either distant or
within the high-dose volume and not in the initially PET negative
elective nodal regions. This suggests that PET/CT-based radiation
therapy planning obviates elective nodal irradiation even in small-
cell lung cancer. Although PET-deﬁned mediastinal radiotherapy
ﬁelds appear to be safe, because of a false-positive rate of approx-
imately 30%, ideally pathological conﬁrmation of PET-positive
mediastinal nodes should be obtained by mediastinoscopy or
endoscopic ultrasound-guided ﬁne needle aspiration (EUS-FNA).
In squamous cell carcinoma, sensitivity for mediastinal metastases
was similar between EUS-FNA and FDGPET/CT (97.9 vs. 96.3%).
However in adenocarcinoma, EUS-FNA shows higher sensitivity
(94.6 vs. 77.8%; Hwangbo et al., 2009), prompting the authors
to suggest pathological staging in case of adenocarcinoma with
negative PET.
F18 FDG PET/CT frequently up stages the overall disease by
detecting unsuspected distant metastasis (>20% of pre-PET stage
III), commonly in liver, adrenal, and bone as well as identiﬁes
patients with very advanced loco regional (occult stage IIB–
IIIB) disease (Mac Manus et al., 2001b). Thus, PET/CT staging
is important in minimizing the rate of futile thoracotomies for
patients with occult systemic disease. In a large prospective trial,
30% of patients who were candidates for high-dose radiother-
apy on the basis of conventional staging received only palliative
therapies after PET, because of unexpected distant metastasis
(20%) or very extensive intrathoracic disease (10%; Mac Manus
et al., 2001a).
PET/CT has signiﬁcantly improved the accuracy of staging for
NSCLC and thus improved oncologists’ ability to give the appro-
priate treatment for the correct stage. A prospective study of 105
consecutive patients with NSCLC showed that the addition of PET
changed management from curative to palliative intent in 26% of
patients and changed overall management in 67% (Kalff et al.,
2001). In a large study of 153 patients with NSCLC, PET changed
the stage of 33%of the patients and changed the target volumes for
radiation in 25% (Hicks et al., 2001). The interobserver as well as
intraobserver variability was signiﬁcantly reduced when the F18
FDG PET imaging was available for tumor volume delineation
(Fox et al., 2005).
GROSS TUMOR VOLUME DELINEATION WITH F18
PET/CT-OPTIMUM THRESHOLDING
Gross TumorVolume (GTV) delineation based on hypermetabolic
tumor has shown to be signiﬁcantly different from GTV drawn on
CT only (Bradley et al., 2004). PET/CT-based planning offers the
potential of dose escalation to the tumor regions with the highest
FDG uptake in order to potentially achieve improved local control
as well as reduced excessive dose to organs at risk such as the lung,
heart, and esophagus. In several planning studies, it was shown
that GTVs based on PET were smaller than that with CT, thus
leading to improved dosimetry to the organs at risk (Møller et al.,
2011). Hanna et al. (2010) performed a second PET/CT for RT
planning in 28 patients with stage IA-IIB NSCLC who already had
undergone a staging PET/CT to assess the effect of additional plan-
ning PET/CT for GTV deﬁnition compared to CT-based planning
alone. There was a signiﬁcant reduction in interobserver variation
for GTV delineation with the use of a planning PET/CT. There was
a mean increase in GTV size of 18.8% using PET/CT compared to
CT only planning for patient treated with radiotherapy only. For
patients who received neoadjuvant chemotherapy, the GTV size
using PET/CT was lower by only 5.2% (Figures 7 and 8).
Meng et al. (2012) correlated microscopic extension of tumor
on histopathology with SUVmax and GTV in NSCLC and found
that microscopic extension is larger in tumors with higher
SUVmax. The study suggested that margins of 1.93, 3.90,
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FIGURE 5 |Target volume contours of the same patient as Figure 2A based on the initial PET/CT data withVOI defining the GTV and PTV excluding
collapsed lung tissue.
and 9.60 mm for SUVmax ≤5, 5–10, and >10 added to the
GTV would be adequate to cover 95% of microscopic tumor
extensions.
PET/CT-based contouring for radiation therapy planning was
compared to CT-based planning in 50 lung cancer patients who
underwent radiotherapywith a curative intent (MacManus,2010).
Radiation dose was planned for 60 Gy delivered in 30 fractions
over 6 weeks. The study demonstrated that 37% patients would
have had a grade I geographic miss and 26% would have had
a grade II geographic miss if radiotherapy planning was done
without the use of PET imaging. A grade I geographic miss
is deﬁned as inadequate GTV coverage, while a grade II geo-
graphic miss is deﬁned as inadequate coverage of PTV excluding
the GTV.
The Radiation Therapy Oncology Group (RTOG) 0515 is a
phase II prospective trial designed to quantify the impact of
PET/CT compared with CT alone on radiation treatment plans
(RTPs) in NSCLC (Bradley et al., 2012). Forty-seven patients
underwent FDG PET/CT followed by deﬁnite RT (>60 Gy)
based on PET/CT- generated radiation plan. Mean follow-up
was for 12.9 months. GTVs derived from PET/CT were signiﬁ-
cantly smaller than that from CT only (mean GTV volume 86.2
vs. 98.7 ml). PET/CT changed nodal GTV contours in 51% of
the patients. The elective nodal failure rate for GTVs derived by
PET/CT was very low, supporting the RTOG standard of limiting
the target volume to the primary tumor and involved nodes. Not
surprisingly, mean lung dose using PET/CT-based planning was
slightly lower than that with CT planning alone. However, there
was no difference in the mean esophageal dose.
Although a ﬁxed threshold to the highest standardized uptake
value (SUV) for generating target volumes on PET has been
used extensively, studies suggest that an adaptive thresholding
approach is more suitable. Biehl et al. (2006) compared PET-
based VOI using varying threshold levels compared to CT-based
target volumes in 20 peripheral lung tumors with volumes in
which the target volume is easily identiﬁed on the CT. The opti-
mal PET threshold for the best match was tumor size-dependent;
it was 15% of SUVmax for tumors larger than 5 cm and 42%
of SUVmax for tumors less than 3 cm. Thus adaptive thresh-
olding based on tumor size and SUVmax may result in a more
customized manner of deﬁning the GTV. However, this is an
area of controversy and active research. The optimal thresh-
old for SUV for the speciﬁc use of target deﬁnition is still
unknown.
DOSE ESCALATION BASED ON SUV THRESHOLDS
Local failure rates are high in NSCLC following radiation ther-
apy, up to 50%. If PET-based parameters such as SUV can
predict sub-volume of the GTV at the highest risk for local recur-
rence after radiotherapy, than this information can be used for
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FIGURE 6 | SBRT dose wash for the same patient as Figure 2A with dose color wash [highest dose (50 Gy) in red delivered to the PTV]. Data courtesy
of UCLA Radiation Oncology.
dose-intensifying the radio-resistant sub-volumes. Along this line,
it has been shown that areas with the highest FDG uptake in the
pre-therapy scans are the sites with the highest risk for local fail-
ure, suggesting escalating the dose to this sub-volumemay improve
local control. Aertis et al. (2009) performed pre and post F18 FDG
PET/CT in 55 inoperable stage I–III NSCLC patients. Patients
with residual metabolic-active areas within the tumors had a sig-
niﬁcantly worse survival compared to individuals with a complete
metabolic response (CMR). The residual metabolic-active areas
within the tumor largely corresponded with the volume that has
a threshold of 50% of the SUVmax in the pre-radiotherapy scan.
Thus a boost to a sub-volume encompassing the 50% SUVmax
sub-volume is a reasonable strategy to improve local control.
In another similar study by Abramyuk et al. (2009), 10 patients
with locoregional relapse of NSCLC underwent F18 FDG PET/CT
before, during, and in the 4–12 months following curative
chemoradiotherapy (dose 66 Gy). CT showed partial reduction of
tumor volume after radiotherapy in all patients. PET/CT revealed
partial response in eight patients and CMR in two patients during
RT. Six to nine months after RT all patients had a local failure.
Tumor recurrences were localized mostly in the areas with highest
metabolic activity in the pre therapy PET/CT. This suggests that
these areas with high metabolic activity are potentially the most
radio-resistant. Thus, another strategy is to dose intensify areas
of the highest metabolic activity based on the pre-treatment FDG
PET/CT.
Feng et al. (2009) performed F18 FDG PET/CT in 14 patients
with stage I–III NSCLC before RT and in mid-RT (after 40–50 Gy).
3D conformal RT plans were generated for each patient, ﬁrst using
only pre-treatment CT scans. Mid-RT PET volumes were then
used to design boost ﬁelds. Mid-RT PET scan-based modiﬁcation
of radiation therapy plans allowed meaningful dose escalation of
30–102 Gy (mean 58 Gy) or decrease in the normal tissue com-
plication probability in 10 of the 14 patients studied. There was a
mean decrease in tumor volume after 40–50 Gy of 26% on CT and
44% by PET/CT. The study concluded that there is a signiﬁcant
change in the tumor metabolic activity as well as the metabolic
volume after 40–50 Gy and adaptation of RT based on the mid-
treatment PET/CT can help to escalate dose to active tumor as well
as reduce dose to critical organs.
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FIGURE 7 | A centrally located left upper lobe tumor. F18 FDG PET/CT
shows large FDG avid mass without mediastinal metastases. Integrated
contrast CT deﬁnes the relationship of tumor with adjacent aorta and
pulmonary vessels. Automated 3D contouring of metabolically avid tumor
was performed using a threshold of 40% of SUVmax. Volume of interest
was exported as RT structure set for radiation planning.
FIGURE 8 | GTV (red line) drawn based on 40% SUVmax threshold
using an automated volume of interest (VOI) definition of
metabolically tumor. Clinical target volume (green line) and planning
target volume (yellow line) generated by adding 0.5 cm and 1 cm margin
to the GTV. Data courtesy of Karolinska Institute Sweden.
van Der Wel et al. (2005) compared CT and PET/CT-based
planning in 21 NSCLC patients, with the goal to deliver 60 Gy
in 30 fractions. F18 FDG PET/CT-based PTV was associated with
reduceddose to the esophagus andnormal lung and allowed signif-
icant radiation dose escalationwhile respecting all relevant normal
tissue constraints. Based on FDG PET/CT planning, the mean
esophageal V (45 Gy) decreased from 45.2 to 34.0% and the mean
esophageal dose from 29.8 to 23.7 Gy. Similarly, average lung
V (Hicks et al., 2001) decreased from 24.9 to 22.3% with slight
decrease of the mean lung dose. For the same dose delivered to
the lung, esophagus, and spinal cord, the mean dose to the target
volume could be increased from 56 Gy with CT-based planning to
71 Gy with FDG PET/CT-based planning.
RELATIONSHIP OF METABOLIC TUMOR VOLUME AND
TUMOR PROGRESSION
Stage at presentation is the primary prognostic factor in NSCLC.
Tumor metabolic activity, as estimated by the SUV, is a prognos-
tic factor in patients with NSCLC. MTV or the volume of tumor
tissue demonstrating increased FDGuptake on PET, including pri-
mary tumor as well as metastases, is another independent adverse
prognostic factor. Lee et al. (2012) evaluated 61 primary NSCLC
patients (39 treated with curative intent while 22 treated with
palliative intent) with F18 FDG PET/CT before and after ther-
apy. MTV was found to be an independent prognostic factor after
accounting for all traditional prognostic variables (stage, perfor-
mance status, weight loss, etc.). In the subset of patients treated
with a curative intent, i.e., stage I–III patients, higher MTV was
signiﬁcantly associated with worse survival and associated with a
trend toward worse progression-free survival. Patients with MTV
below the median for the respective therapy group showed higher
PFS. The 2-year PFS for patients with MTV below median was
60 vs. 39.7% for those with higher MTV (median PFS 34.9 vs.
11.9 months).
GATED PET/CT-BASED PLANNING
Respiratory motion of lung tumors is a key factor which impacts
radiation dose delivery to the tumor as well as irradiation of nor-
mal lung tissue. Respiratory motion can be as large as 3 cm for
lesions in lung bases. One study (Hamill et al., 2008) reported that
the rangeof tumormotionvaried from8 to25mmamongﬁve lung
cancer patients. Respiratory motion assessment can also improve
intratherapy modiﬁcation of treatment plan to adapt to changes
in tumor volume and motion during the treatment course.
Accurate estimationof motion and incorporationof such infor-
mation into treatment planning is essential for SBRT as well as
conventionally fractionated treatments with dose escalation. 4D
CT-based planning has been widely used to account for motion
in order to achieve smaller margins and reduce dose to normal
tissue. In a study involving 10 NSCLC patient treated with SBRT
(Wang et al., 2009), 4D CT-based planning provided the small-
est treatment volume, permitted higher doses per fraction, and
reduced doses to the normal lung compared to standard CT-based
planning. However, studies have shown that fast CT imaging of
a moving tumor can result in poor representation of the time –
averaged position and shape of the tumor. In a phantom-based
study (Caldwell et al., 2003) PET imaging provided a more accu-
rate representation of 3D volume of phantom tumors compared
to gated CT.
Respiratory-correlated PET ameliorates motion blurring and
enables visualization of lung tumor functional uptake through-
out the breathing cycle but has achieved limited clinical use in
radiotherapy planning. Tumor volumes generated by 4D CT and
respiratory-gated PET were compared by Lamb et al. (2011) in
four lower lobe lung tumors (4–18 cc in volume) in three patients.
GTVs incorporating tumor motion were generated by combin-
ing tumor contours from multiple PET respiratory phase data as
well as ungated PET images using standard tumor thresholding
approach. GTV using CT was generated by combining end inspi-
ration and end expiratory phases of 4D CT. The GTV volumes
generated by gated PET were on an average 30% lower than that
generated by 4D CT. Volumes generated by ungated PET was also
lower than that of 4DCTbut the differencewas smaller. Gated PET
is particularly useful in lower lobe tumors with signiﬁcant motion
for SBRT planning and allows for more accurate representation of
tumor motion than a 4D CT. 4D CT is often inaccurate for lesions
in the lower lobe due to tumor proximity to soft tissue like the
liver on the right side and stomach/spleen on the left side with the
attendant decrease in the accuracy of tumor motion assessment.
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Bosmans et al. (2006) assessed 23 patientswith locally advanced
NSCLC who underwent F18 FDG PET/CT as well as respiratory-
gated CT prior to treatment, and repeated at the ﬁrst and second
weeks after the start of radiation. The changes in tumor motion
during radiation therapy were relatively small. However, there was
a great deal of variation in tumor size during therapy, ranging from
30% increase to similar decrease in tumor volume. The authors
concluded that such changes in tumor size required replanning
preferably with evaluation of tumor motion during the course of
therapy (Figures 9 and 10).
PET/CT-BASED RADIATION THERAPY FOLLOW-UP AND
RECURRENCE DETECTION
The SUVmaxof primaryNSCLChas been shown to be of prognos-
tic value for survival outcomes. Correlation of pre- and post-RT
SUVmax to overall survival as well as disease free survival shows
FIGURE 9 | NSCLC at right lung base. F18 FDG PET/CT shows
hypermetabolic tumor mass close to diaphragm and posterior thoracic
wall without nodal or distant metastases. Respiratory-gated PET/CT was
performed. Images show end inspiratory (pink) and end expiratory (yellow)
metabolic tumor volumes superimposed on non-gated PET/CT image
demonstrating tumor motion during the entire respiratory cycle.
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FIGURE 10 | Same patient as in Figure 4A with GTV (pink), CTV (blue), and PTV (green) drawn using a combination of end expiratory and end
inspiratory metabolically active tumor volume as obtained from respiratory-gated PET/CT.
that higher SUVmax in primary tumor and nodal metastases was
associated with poor survival (Liao et al., 2012). This is related
to the fact that tumor glucose uptake may correlate with the
metastatic potential.
The value of FDG PET in evaluation of response to RT has
been established. In a series of 88 NSCLC patients (Mac Manus
et al., 2005) who underwent pre- and post-chemo/RT (median 70
days after initiation of RT of 60 Gy in 30 fractions over 6 weeks),
45% had CMR and 36% PMR (partial metabolic response) on
FDG PET. Median survival for CMR and non-CMR patients was
31 and 11 months, respectively. One-year survival for CMR and
non-CMR patients was 93 and 47%, respectively. This demon-
strates the impact of CMR on follow-up PET after RT as a
predictive marker of outcomes despite confounding issues such
as radiotherapy-induced inﬂammation.
SUVmax changes during radiotherapy are signiﬁcantly differ-
ent between metabolic responders and non-responders. Metabolic
responders have a better overall survival than the non-responders.
Percentage decrease in SUVmax following RT directly correlates
with disease-free survival (Lopez Guerra et al., 2012). Metabolic
non-responders have beendemonstrated tohave a higher SUVmax
at all time points investigated and showed a signiﬁcant increase
in SUVmax during the ﬁrst week of irradiation followed by a
decrease. In contrast, the responders showed a stable SUVmax
during irradiation. The increase of SUVmax during the ﬁrst week
of RT was probably due to inﬂammation, since a rather high
median dose of 19.8 Gy (1.8 Gy BID) was already delivered at
the time point of the ﬁrst repeat PET/CT scan.
FDG PET/CT-based response evaluation for lung tumors
undergoing radiation therapy is often complicated due to post-
radiation inﬂammation. Hicks et al. (2004) assessed the relation-
ship of post-radiation inﬂammatory changes in irradiated normal
lung tissue and metabolic response in tumor in 73 patients with
NSCLC. Metabolic response of tumor was greater in patients
with higher inﬂammation-related FDG uptake in normal lung
suggesting that tumor radio-responsiveness and normal tissue
radiosensitivity may be linked. Inﬂammatory changes did not
compromise evaluation of prognostic stratiﬁcation by PET as long
as a meticulous visual response assessment criterion was used.
PETalso plays a role in detecting recurrent disease. Scarring and
post-operative changes complicate interpretation of CT images
and needle biopsy results are inconclusive in up to 30% patients
(Mesurolle et al., 2003). Metabolic imaging with PET/CT however
shows a high accuracy (between 78 and 98%) in post-therapy
NSCLC for recurrence detection (Erasums and Patz, 1999).
Because post-radiation pneumonitis and inﬂammation are more
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common immediately after treatment, increasing the interval
between the end of radiation therapy and the PET scan provides
a greater speciﬁcity for abnormal ﬁndings. Earliest recommended
interval is 6 weeks while 4–6 months interval is common practice.
Metabolic response assessment is often used as a surrogate of
local failure and survival. Early identiﬁcation of patients with
residual metabolic activity is essential as this enables selection of
patients who could potentially beneﬁt from additional therapy.
Velasquez et al. (2010) performed pre and post radical chemo/RT
PET/CT in 101 patients with inoperable NSCLC and found signif-
icantly reduced overall survival in patients with residual metabolic
active areas in post therapy PET. Large tumors and tumors with
higher SUVmax were more likely to be associated with residual
metabolically active tumor at end of RT.
Sequential PET/CT imaging during radiation therapy has been
shown to be beneﬁcial for accurate evaluation of therapy response
despite the issues related to post-radiation inﬂammation. Edet-
Sanson et al. (2012) performed FDG PET/CT before and during
radiation therapy (60–70 Gy, 2 Gy per fraction, 5 fractions per
week) in 10 NSCLC patients. PET/CT was performed every seven
fractions (14 Gy total dose increments) with all patients under-
going 5–6 PET/CT studies. All 17 lesions (6 tumors and 11 nodal
metastases) showed progressive decrease in SUVmax with increase
in cumulative radiation dose. A 50% decrease in SUV max was
obtained around a total dose of 45–50 Gy (during week 5 of RT).
Because of the increased FDG uptake in inﬂammation sec-
ondary to radiation therapy in lung cancer that can complicate
PET/CT evaluation of response to radiation therapy, FLT, a prolif-
eration agent has been advocated for RT follow-up. FLT is felt to
have a lower level of uptake in inﬂammation compared to prolif-
erating tumor cells. A pilot study (Everitt et al., 2009) performed
baseline FDG and FLT PET/CT studies as well as follow-up FLT
PET/CT studies on day 2,8,15, and 29 of radiation therapy for a
multi-time point evaluation of RT response. Baseline FLT uptake
corresponded to FDG avid regions although the uptake levels were
lower with FLT. Sequential FLT studies during therapy demon-
strated a progressive decrease of uptake with a mean decrease of
58% in SUV on day 29 compared to baseline. A marked reduction
of (Mac Manus et al., 2001a) FLT uptake in irradiated bone mar-
row was observed for all cases. This reduction was observed even
after only 2 Gy, and all patients demonstrated a complete absence
of proliferating marrow after 10 Gy.
CONCLUSION
F18 FDG PET/CT-based radiation therapy planning for NSCLC
is able to improve GTV deﬁnition and dose escalation by accu-
rately deﬁningmediastinalmetastases aswell as differentiate viable
tumor from atelectasis and necrosis. PET/CT study prior to ther-
apy provides valuable prognostic information from SUV, SUV
max, MTV etc. that helps guide the intensity and targeting of
the planned radiotherapy. PET/CT-based RT planning is able to
achieve clinically meaningful dose escalation while limiting dose
to organs at risk. Adaptive RT planning, which uses mid-therapy
PET/CT for dose modiﬁcations, can achieve further dose escala-
tion and improve tumor control probability. Sequential PET/CT
imaging has also been shown to be valuable in the evaluation of
tumor response to radiation and recurrence detection. Current
research with new biomarkers such as proliferation and hypoxia
biomarkers show promise by incorporating different types of
metabolic information. This will be important for rationale radi-
ation dose painting and assisting future patient-centric adaptive
radiotherapy.
Data courtesy of M. D. Anderson, Cancer Center, Orlando,
FL, USA.
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